Dopaminergic neuroprotection by neurturin-expressing c17.2 neural stem cells in a rat model of Parkinson's disease

Parkinsonism and Related Disorders

Volumn 13, Issue 2, 2007, Pages 77-88

  Liu, Wei Guo ^a   Lu, Guo Qiang ^a   Li, Biao ^a   Chen, Sheng Di ^a,b  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

Author keywords

Neural stem cell; Neuroprotection; Neurturin; Parkinson's disease

Indexed keywords

NEUROTRANSMITTER; NEURTURIN; OXIDOPAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL TRANSPLANTATION; CIRCLING BEHAVIOR; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NERVE CELL; NEURAL STEM CELL; NEUROPROTECTION; NONHUMAN; OLIGODENDROGLIA; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SUBSTANTIA NIGRA;

ADRENERGIC AGENTS; ANIMALS; APOMORPHINE; BEHAVIOR, ANIMAL; CELL COUNT; CELL LINE; DISEASE MODELS, ANIMAL; DOPAMINE; MALE; MOTOR ACTIVITY; NERVE TISSUE PROTEINS; NEUROPROTECTIVE AGENTS; NEURTURIN; OXIDOPAMINE; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; STEM CELL TRANSPLANTATION; STEM CELLS; TYROSINE 3-MONOOXYGENASE;

EID: 33847254416     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2006.07.015     Document Type: Article

References (54)

1. McGeer P.L., Itagaki S., Akiyama H., and McGeer E.G. Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol 24 4 (1988) 574-576
2. Olanow C.W., and Tatton W.G. Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci 22 (1999) 123-144
3. Betchen S.A., and Kaplitt M. Future and current surgical therapies in Parkinson's disease. Curr Opin Neurol 16 4 (2003) 487-493
4. Burton E.A., Glorioso J.C., and Fink D.J. Gene therapy progress and prospects: Parkinson's disease. Gene Ther 10 20 (2003) 1721-1727
5. Dunnett S.B., and Bjorklund A. Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Nature 399 Suppl. 6738 (1999) A32-A39
6. Vajda F.J. Neuroprotection and neurodegenerative disease. J Clin Neurosci 9 1 (2002) 4-8
7. Oransky I. Gene therapy trial for Parkinson's disease begins. Lancet 362 9385 (2003) 712
8. Akerud P., Alberch J., Eketjall S., Wagner J., and Arenas E. Differential effects of glial cell line-derived neurotrophic factor and neurturin on developing and adult substantia nigra dopaminergic neurons. J Neurochem 73 1 (1999) 70-78
9. Tomac A., Lindqvist E., Lin L.F., Ogren S.O., Young D., Hoffer B.J., et al. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 373 6512 (1995) 335-339
10. Lin L.F., Doherty D.H., Lile J.D., Bektesh S., and Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260 5111 (1993) 1130-1132
11. Beck K.D., Valverde J., Alexi T., Poulsen K., Moffat B., Vandlen R.A., et al. Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain. Nature 373 6512 (1995) 339-341
12. Kotzbauer P.T., Lampe P.A., Heuckeroth R.O., Golden J.P., Creedon D.J., Johnson Jr. E.M., et al. Neurturin, a relative of glial-cell-line-derived neurotrophic factor. Nature 384 6608 (1996) 467-470
13. Golden J.P., DeMaro J.A., Osborne P.A., Milbrandt J., and Johnson Jr. E.M. Expression of neurturin, GDNF, and GDNF family-receptor mRNA in the developing and mature mouse. Exp Neurol 158 2 (1999) 504-528
14. Leitner M.L., Molliver D.C., Osborne P.A., Vejsada R., Golden J.P., Lampe P.A., et al. Analysis of the retrograde transport of glial cell line-derived neurotrophic factor (GDNF), neurturin, and persephin suggests that in vivo signaling for the GDNF family is GFRalpha coreceptor-specific. J Neurosci 19 21 (1999) 9322-9331
15. Horger B.A., Nishimura M.C., Armanini M.P., Wang L.C., Poulsen K.T., Rosenblad C., et al. Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons. J Neurosci 18 13 (1998) 4929-4937
16. Oiwa Y., Yoshimura R., Nakai K., and Itakura T. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease. Brain Res 947 2 (2002) 271-283
17. Lindner M.D., Winn S.R., Baetge E.E., Hammang J.P., Gentile F.T., Doherty E., et al. Implantation of encapsulated catecholamine and GDNF-producing cells in rats with unilateral dopamine depletions and parkinsonian symptoms. Exp Neurol 132 1 (1995) 62-76
18. Beck K.D., Valverde J., Alexi T., Poulsen K., Moffat B., Vandlen R.A., et al. Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain. Nature 373 6512 (1995) 339-341
19. Bowenkamp K.E., Hoffman A.F., Gerhardt G.A., Henry M.A., Biddle P.T., Hoffer B.J., et al. Glial cell line-derived neurotrophic factor supports survival of injured midbrain dopaminergic neurons. J Comp Neurol 355 4 (1995) 479-489
20. Tomac A., Lindqvist E., Lin L.F., Ogren S.O., Young D., Hoffer B.J., et al. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 373 6512 (1995) 335-339
21. Kearns C.M., and Gash D.M. GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo. Brain Res 672 1&2 (1995) 104-111
22. Kirik D., Georgievska B., Rosenblad C., and Bjorklund A. Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson's disease. Eur J Neurosci 13 8 (2001) 1589-1599
23. Gash D.M., Zhang Z., Ovadia A., Cass W.A., Yi A., Simmerman L., et al. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 380 6571 (1996) 252-255
24. Gill S.S., Patel N.K., Hotton G.R., O'Sullivan K., McCarter R., Bunnage M., et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 9 5 (2003) 589-595
25. Ostenfeld T., Tai Y.T., Martin P., Deglon N., Aebischer P., and Svendsen C.N. Neurospheres modified to produce glial cell line-derived neurotrophic factor increase the survival of transplanted dopamine neurons. J Neurosci Res 69 6 (2002) 955-965
26. Akerud P., Canals J.M., Snyder E.Y., and Arenas E. Neuroprotection through delivery of glial cell line-derived neurotrophic factor by neural stem cells in a mouse model of Parkinson's disease. J Neurosci 21 20 (2001) 8108-8118
27. Snyder E.Y., Deitcher D.L., Walsh C., Arnold-Aldea S., Hartwieg E.A., and Cepko C.L. Multipotent neural cell lines can engraft and participate in development of mouse cerebellum. Cell 68 1 (1992) 33-51
28. Harding A.J., Halliday G.M., and Cullen K. Practical considerations for the use of the optical disector in estimating neuronal number. J Neurosci Meth 51 1 (1994) 83-89
29. Dauer W., and Przedborski S. Parkinson's disease: mechanisms and models. Neuron 39 6 (2003) 889-909
30. Foley P., and Riederer P. Influence of neurotoxins and oxidative stress on the onset and progression of Parkinson's disease. J Neurol 247 Suppl. 2 (2000) II82-II94
31. Jenner P., and Olanow C.W. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 47 6 Suppl. 3 (1996) S161-S170
32. Jenner P. Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease. Acta Neurol Scand Suppl 146 (1993) 6-13
33. Rosenblad C., Kirik D., Devaux B., Moffat B., Phillips H.S., and Bjorklund A. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle. Eur J Neurosci 11 5 (1999) 1554-1566
34. Ungerstedt U. 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur J Pharmacol 5 1 (1968) 107-110
35. Przedborski S., Levivier M., Jiang H., Ferreira M., Jackson-Lewis V., Donaldson D., et al. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience 67 3 (1995) 631-647
36. Sauer H., and Oertel W.H. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 59 2 (1994) 401-415
37. Schober A. Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res 318 1 (2004) 215-224
38. Hudson J.L., van Horne C.G., Stromberg I., Brock S., Clayton J., Masserano J., et al. Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats. Brain Res 626 1&2 (1993) 167-174
39. Bradley J.A., Bolton E.M., and Pedersen R.A. Stem cell medicine encounters the immune system. Nat Rev Immunol 2 11 (2002) 859-871
40. Draper J.S., Pigott C., Thomson J.A., and Andrews P.W. Surface antigens of human embryonic stem cells: changes upon differentiation in culture. J Anat 200 Pt 3 (2002) 249-258
41. Drukker M., Katz G., Urbach A., Schuldiner M., Markel G., Itskovitz-Eldor J., et al. Characterization of the expression of MHC proteins in human embryonic stem cells. Proc Natl Acad Sci USA 99 15 (2002) 9864-9869
42. Paul L.C., and Baldwin III W.M. Humoral rejection mechanisms and ABO incompatibility in renal transplantation. Transplant Proc 19 6 (1987) 4463-4467
43. Cooper D.K. A clinical survey of cardiac transplantation between ABO blood group-incompatible recipients and donors. Transplant Proc 22 4 (1990) 1457
44. Simpson E., Scott D., James E., Lombardi G., Cwynarski K., Dazzi F., et al. Minor H antigens: genes and peptides. Eur J Immunogenet 28 5 (2001) 505-513
45. McLaren F.H., Svendsen C.N., Van der M.P., and Joly E. Analysis of neural stem cells by flow cytometry: cellular differentiation modifies patterns of MHC expression. J Neuroimmunol 112 1&2 (2001) 35-46
46. Fairchild P.J., and Waldmann H. Dendritic cells and prospects for transplantation tolerance. Curr Opin Immunol 12 5 (2000) 528-535
47. Knechtle S.J., Hamawy M.M., Hu H., Fechner Jr. J.H., and Cho C.S. Tolerance and near-tolerance strategies in monkeys and their application to human renal transplantation. Immunol Rev 183 (2001) 205-213
48. Ke B., Coito A.J., Kato H., Zhai Y., Wang T., Sawitzki B., et al. Fas ligand gene transfer prolongs rat renal allograft survival and down-regulates anti-apoptotic Bag-1 in parallel with enhanced Th2-type cytokine expression. Transplantation 69 8 (2000) 1690-1694
49. Swenson K.M., Ke B., Wang T., Markowitz J.S., Maggard M.A., Spear G.S., et al. Fas ligand gene transfer to renal allografts in rats: effects on allograft survival. Transplantation 65 2 (1998) 155-160
50. Wood K.J., Jones N.D., Bushell A.R., and Morris P.J. Alloantigen-induced specific immunological unresponsiveness. Philos Trans R Soc Lond B Biol Sci 356 1409 (2001) 665-680
51. Hurelbrink C.B., and Barker R.A. The potential of GDNF as a treatment for Parkinson's disease. Exp Neurol 185 1 (2004) 1-6
52. Deglon N., Tseng J.L., Bensadoun J.C., Zurn A.D., Arsenijevic Y., Pereira de Almeida L., et al. Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease. Hum Gene Ther 11 1 (2000) 179-190
53. McGrath J., Lintz E., Hoffer B.J., Gerhardt G.A., Quintero E.M., and Granholm A.C. Adeno-associated viral delivery of GDNF promotes recovery of dopaminergic phenotype following a unilateral 6-hydroxydopamine lesion. Cell Transplant 11 3 (2002) 215-227
54. Nutt J.G., Burchiel K.J., Comella C.L., Jankovic J., Lang A.E., Laws Jr. E.R., et al. ICV GDNF Study Group. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 60 1 (2003) 69-73